Overview
EGPA (formerly Churg-Strauss syndrome) is a rare, small-to-medium vessel necrotizing vasculitis characterized by asthma, eosinophilia, and extravascular granulomas. It commonly affects the lungs, skin, peripheral nerves, and heart. Annual incidence: ~1–3 per million; peak onset in 40s–60s; no significant gender bias. Strongly associated with MPO-ANCA positivity in ~40–60% of patients; others are ANCA-negative.
Definition
Eosinophilia: abnormally high number of eosinophils in the blood or tissues, which is a hallmark feature of EGPA and often appears before vasculitic symptoms.
Granuloma: localized collection of inflammatory cells, such as macrophages and giant cells, and in EGPA these extravascular granulomas contribute to tissue and organ damage.
ANCA (Anti-Neutrophil Cytoplasmic Antibodies): autoantibodies against proteins in neutrophils, found in around 40% of EGPA patients, and are linked to clinical features such as glomerulonephritis and neuropathy.
Physiology
Eosinophil Function
- Primary role: Defense against parasites and involvement in allergic and eosinophilic inflammatory responses
- Cytotoxic action via release of:
- Major Basic Protein (MBP) – damages parasites, host tissue
- Eosinophil Cationic Protein (ECP) – antiviral, cytotoxic
- Eosinophil Peroxidase (EPO) – generates reactive oxygen species
- Eosinophil-Derived Neurotoxin (EDN) – neurotoxic effects
- Contribute to tissue damage and fibrosis in diseases like EGPA, asthma, and eosinophilic esophagitis
- Regulate local immune response by releasing cytokines, chemokines, and lipid mediators (e.g., leukotrienes)
| Key Cytokines in Eosinophil Production and Activation | |
| Cytokine | Function |
| IL-5 | Most important; stimulates eosinophil growth, differentiation, activation, and survival in tissues |
| IL-3 | Promotes early eosinophil progenitor development from bone marrow |
| GM-CSF | Enhances eosinophil activation and prolongs survival |
| IL-4 / IL-13 | Promote Th2 differentiation, leading to more IL-5 production |
| Eotaxins (CCL11, CCL24) | Chemokines that recruit eosinophils to sites of inflammation (especially in lungs and GI tract) |
Remember
IL-5 is the central cytokine in eosinophilic disorders. Targeting IL-5 (e.g., with mepolizumab) is effective in EGPA, severe eosinophilic asthma, and HES.
Aetiology and Risk Factors
Aetiology
- Idiopathic; suspected immune dysregulation with eosinophilic activation
- Hypersensitivity response to allergens or autoantigens
Risk Factors
- History of asthma or allergic rhinitis
- Atopy, nasal polyposis
- Certain medications (e.g., leukotriene receptor antagonists like montelukast, though likely unmasking latent disease)
Pathophysiology
- Phase 1: Prodromal (Allergic phase)
- Chronic rhinosinusitis, asthma, nasal polyps
- Eosinophilic asthma
- Phase 2: Eosinophilic phase
- Marked blood and tissue eosinophilia → eosinophilic pneumonitis, gastroenteritis
- Phase 3: Vasculitic phase
- Necrotizing vasculitis ± granulomas of small/medium vessels; systemic organ damage (nerves, skin, heart)
Think
If a patient with eosinophilic asthma develops neuropathy, purpura, or systemic symptoms, always consider EGPA.
Clinical Manifestations
- ENT & Respiratory
- Adult-onset asthma (nearly universal)
- Nasal polyps, allergic rhinitis
- Pulmonary infiltrates (transient, patchy)
- Pleural effusion, hemoptysis (rare)
- Mononeuritis multiplex (~70%): foot drop, wrist drop
- Skin: Palpable purpura, nodules, livedo reticularis
- Cardiac: Myocarditis, pericarditis, heart failure; leading cause of death
- Renal: Mild proteinuria, hematuria. Glomerulonephritis less common than in GPA/MPA
- Eosinophilic gastroenteritis
Remember
Cardiac involvement is the most important prognostic factor.
Remember
Unlike GPA/MPA, mononeuritis multiplex and cardiac involvement is common in EGPA.
Diagnosis
Classification Criteria (2022 ACR/EULAR)
| Entry Requirement: A diagnosis of small- or medium-vessel vasculitis has been made (biopsy), and other mimicking conditions have been excluded. | |||
| Variables | GPA | MPA | EGPA |
| Clinical criteria | |||
| Nasal passage involvement | +3 | −3 | — |
| Cartilaginous involvement | +2 | — | — |
| Conductive or sensorineural hearing loss | +1 | — | — |
| Obstructive airway disease | — | — | +3 |
| Nasal polyp | — | — | +3 |
| Mononeuritis multiplex | — | — | +1 |
| Laboratory criteria | |||
| PR3-ANCA (or C-ANCA) positivity | +5 | −1 | −3 |
| MPO-ANCA (or P-ANCA) positivity | −1 | +6 | — |
| Serum eosinophil ≥1000/µL | −4 | −4 | +5 |
| Hematuria | — | — | −1 |
| Histological criteria | |||
| Granuloma, granulomatous inflammation, or giant cells | +2 | — | — |
| Pauci-immune glomerulonephritis | +1 | +3 | — |
| Extravascular eosinophilic-predominant inflammation | — | — | +2 |
| Radiological criteria | |||
| Pulmonary nodules, mass, or cavitation on chest imaging | +2 | — | — |
| Fibrosis or ILD on chest imaging | — | +3 | — |
| Nasal/paranasal sinusitis or mastoiditis on imaging | +1 | — | +1 |
| Total Score Cut-off for Classification | ≥5 | ≥5 | ≥6 |
Investigations
- Eosinophilia ≥10%
- ANCA panel: MPO-ANCA positive (~40–60%)
- ESR/CRP: elevated
- IgE: usually elevated
- Imaging: CT chest (transient infiltrates, effusions)
- Biopsy (skin, nerve, lung): eosinophilic infiltration ± granulomas
Differential Diagnoses
| Diagnosis | Key Differences |
| Eosinophilic asthma | Chronic airway inflammation with mild to moderate eosinophilia. Only lung involvement, no systemic vasculitis. |
| Hypereosinophilic syndrome | Persistent eosinophilia without vasculitis or parasitic infection |
| Allergic bronchopulmonary aspergillosis | Asthma + eosinophilia, but lacks systemic vasculitis |
Treatment
| Phase | Treatment |
| Mild (non-severe) | Glucocorticoids taper ± Mepolizumab |
| Severe (organ/life-threatening) | High-dose glucocorticoids + cyclophosphamide or rituximab |
| Maintenance | Glucocorticoid taper + Mepolizumab, azathioprine, methotrexate, or rituximab |
Supportive
- Pneumocystis prophylaxis (e.g. TMP-SMX)
- Cardiac monitoring if involvement suspected
- Vaccinations (influenza, pneumococcal, shingles)
Complications and Prognosis
Complications
- Heart failure (due to myocarditis)
- GI perforation
- Relapsing neuropathy
- Steroid toxicity
Prognosis
- 5-year survival ~80–90%
- Poor prognostic factors (Five-Factor Score):
- Proteinuria >1g/day
- Renal insufficiency
- GI involvement
- Cardiomyopathy
- CNS involvement
References
- Groh M et al. JAMA. 2013;309(20):2068–2075.
- Jennette JC et al. Kidney Int. 2013;83(2):227–234.
- Robson JC et al. Ann Rheum Dis. 2022;81(3):309–320.
- Comarmond C et al. Arthritis Rheum. 2013;65(11):3176–3182.
- Samson M et al. Eur Respir Rev. 2017;26(145):170083.
Discussion